東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Reducing the time to market for new ...

Liu, Elliott W.

Linked to FindBook

Google Book

Amazon

博客來

Reducing the time to market for new drugs by managing clinical trial technology and workflow.

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Reducing the time to market for new drugs by managing clinical trial technology and workflow./
Author:	Liu, Elliott W.
Description:	238 p.
Notes:	Adviser: Norman Pearson.
Contained By:	Dissertation Abstracts International64-01A.
Subject:	Business Administration, Management. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3078975

Reducing the time to market for new drugs by managing clinical trial technology and workflow.
Liu, Elliott W.

Reducing the time to market for new drugs by managing clinical trial technology and workflow. - 238 p.

Adviser: Norman Pearson.

Thesis (Ph.D.)--Capella University, 2003.

Clinical trial technology is the application of information technology to the automation of practical processes in clinical development activities. Workflow reengineering has been a dominant movement in many manufacturing industries in the last two decades. The pharmaceutical companies do not broadly recognize the integration of workflow reengineering with clinical trial technology. Although this phenomenon is interdisciplinary, its internal structure and the nature of its interactions with other disciplines in clinical development organizations have not been studied in depth. This research analyzed the empirical data based on descriptive statistics and on performing variability testing as well as correlation and predictive analysis. Four major constructs were investigated to test the premise that pharmaceutical companies, which integrate their clinical trial technology with workflow engineering by integrating processes into overall clinical development methods will show a reduction in time to market for new drugs. Seventy-seven parent pharmaceutical companies were surveyed for this research. Historical review of the 2001 corporate filings extracted and paired with the survey results were used to predict the implications for financial performance of reducing clinical trial delays and elapsed time. Annual based longitudinal research and further studies of the associated measurement of cost components are needed.Subjects--Topical Terms:

626628
Business Administration, Management.

Reducing the time to market for new drugs by managing clinical trial technology and workflow.
LDR:02317nam 2200277 a 45 001 933329
005 20110505
008 110505s2003 eng d
035 $a (UnM)AAI3078975
035 $a AAI3078975
040 $a UnM $c UnM
100 1 $a Liu, Elliott W. $3 1257063
245 1 0 $a Reducing the time to market for new drugs by managing clinical trial technology and workflow.
300 $a 238 p.
500 $a Adviser: Norman Pearson.
500 $a Source: Dissertation Abstracts International, Volume: 64-01, Section: A, page: 0217.
502 $a Thesis (Ph.D.)--Capella University, 2003.
520 $a Clinical trial technology is the application of information technology to the automation of practical processes in clinical development activities. Workflow reengineering has been a dominant movement in many manufacturing industries in the last two decades. The pharmaceutical companies do not broadly recognize the integration of workflow reengineering with clinical trial technology. Although this phenomenon is interdisciplinary, its internal structure and the nature of its interactions with other disciplines in clinical development organizations have not been studied in depth. This research analyzed the empirical data based on descriptive statistics and on performing variability testing as well as correlation and predictive analysis. Four major constructs were investigated to test the premise that pharmaceutical companies, which integrate their clinical trial technology with workflow engineering by integrating processes into overall clinical development methods will show a reduction in time to market for new drugs. Seventy-seven parent pharmaceutical companies were surveyed for this research. Historical review of the 2001 corporate filings extracted and paired with the survey results were used to predict the implications for financial performance of reducing clinical trial delays and elapsed time. Annual based longitudinal research and further studies of the associated measurement of cost components are needed.
590 $a School code: 1351.
650 4 $a Business Administration, Management. $3 626628
650 4 $a Health Sciences, Pharmacy. $3 1017737
650 4 $a Information Science. $3 1017528
690 $a 0454
690 $a 0572
690 $a 0723
710 2 0 $a Capella University. $3 1017687
773 0 $t Dissertation Abstracts International $g 64-01A.
790 $a 1351
790 1 0 $a Pearson, Norman, $e advisor
791 $a Ph.D.
792 $a 2003
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3078975